Note 9 - Stockholders' Equity

9 Months Ended

Sep. 30, 2020

Notes to Financial Statements

Stockholders' Equity Note Disclosure [Text Block]

( 9 ) Stockholders' Equity

2020

Public Offering on Form S-

1

Registration Statement

- In

May 2020,

the Company submitted a Form S-

1

Registration Statement (S-

1

) to the Securities and Exchange Commission (SEC), which was subsequently amended. On

June 17, 2020,

the Company entered into an underwriting agreement with A.G.P./Alliance Global Partners, as representative of the several underwriters named therein, relating to a firm commitment underwritten public offering pursuant to the S-

1,

of

4,762,000

shares of common stock, par value of

$0.001

per share. The offering price to the public was

$2.10

per share. The underwriters were granted a

45

-day option to purchase up to

714,190

additional shares of common stock to cover over-allotments. Such option was exercised in full on

June 18, 2020.

The closing of the offering occurred on

June 19, 2020.

After deducting underwriting discounts and commissions and estimated offering expenses payable by the Company, BioCardia realized net proceeds of approximately

$10.3

million.

Warrants

- Set forth below is a table of activity of warrants for common stock and the related weighted average exercise price per warrant.

	Number of		Weighted
	Common Stock		Average
	Warrants		Exercise Price
Balance, December 31, 2019		2,435,807	$	6.36
Warrants for common stock sold		—		—
Warrants for common stock exercised		—		—
Balance, September 30, 2020		2,435,807	$	6.36